Printer Friendly

RHONE-POULENC RORER ISSUES ANNOUNCEMENT

 RHONE-POULENC RORER ISSUES ANNOUNCEMENT
 COLLEGEVILLE, Pa., June 16 /PRNewswire/ -- Rhone-Poulenc Rorer


(NYSE: RPR) announced today that it was erroneously reported in Paris that earnings for 1992 would be $460 million.
 RPR has not changed any of its projections for 1992. Analyst expectations for 1992 are $3.00 to $3.10 per share. RPR said it remains confident of these current expectations based on a 25-30 percent growth in earnings.
 Rhone-Poulenc Rorer is a global pharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of human pharmaceuticals. In 1991 the company had sales of $3.8 billion, and plans to invest approximately $500 million in research and development in 1992.
 /delval/
 -0- 6/16/92
 /CONTACT: Rhone-Poulenc Rorer media relations, 215-454-3871, or investor relations, 215-454-3851/
 (RPR) CO: Rhone-Poulenc Rorer ST: Pennsylvania IN: MTC SU:


CC -- PH017 -- 0600 06/16/92 10:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 16, 1992
Words:143
Previous Article:IVAX ANNOUNCES JOINT DEVELOPMENT AGREEMENT WITH GLAXO
Next Article:RAYTHEON UNIT, BRITISH AEROSPACE TEAM ON MILITARY TRAINING AIRCRAFT BID
Topics:


Related Articles
RHONE-POULENC RORER AGAIN INCREASES QUARTERLY DIVIDEND
MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS
RHONE-POULENC RORER AGAIN INCREASES QUARTERLY DIVIDEND
RHONE-POULENC PURCHASING SHARES OF RHONE-POULENC RORER TO OFFSET DILUTIVE EVENTS
RHONE-POULENC RORER ISSUES ANNOUNCEMENT
RHONE-POULENC RORER S.A. FILES PATENT INFRINGEMENT LAWSUIT AGAINST BRISTOL-MYERS SQUIBB REGARDING TAXOL(R)
Olympic Gold Medalist Tom Dolan And Rhone-Poulenc Rorer Partner On Asthma Education Program
Launch Of Tender Offer by Rhone-Poulenc For Shares of Rhone-Poulenc Rorer: Agreement Reached on $97 Per Share
Rhone-Poulenc S.A. Successfully Completes Tender Offer For Rhone-Poulenc Rorer Inc.
Rhone-Poulenc Rorer Propharm Announces Measures to Improve Industrial Operations Competitiveness

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters